 |
|
Thyroid-cancer test reveals recurrence early
June 27, 2005COLUMBUS , Ohio - A blood test for thyroid cancer can detect persistent or recurrent disease even before doctors can find any trace of a tumor, according to a new study. The findings suggest that people treated for the disease should be examined regularly for early signs of recurrence.
The study, by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSU CCC - James), examined how well a test for thyroid cancer can predict whether the disease will recur.
The findings were published June 21 online in the Journal of Clinical Endocrinology & Metabolism.
The test measures a protein known as thyroglobulin (Tg), which is made by thyroid-cancer cells. The measurement is taken after a person is injected with a relatively new drug known as thyrotropin alfa, or Thyrogen. The drug allows Tg testing without the sometimes debilitating side effects of hypothyroidism that otherwise accompany the test when stimulation testing is done.
"We were surprised to find that even with relatively low thyroglobulin levels, and even when there is no sign of a tumor, about 80 percent of patients had a recurrence of their cancer within three to five years," says first author Richard T. Kloos, associate professor of internal medicine and of radiology.
"This indicates that we are detecting these tumors very early, and that time and diligence may be needed to find them."
The study also found that even when Tg levels are very low or undetectable, about 2 to 5 percent of patients still have a recurrence after three to five years.
"Currently, some thyroid-cancer treatment guidelines say that these patients may never need further testing, but our data contradict that," says Kloos, co-director of the Thyroid Cancer Unit at the OSU CCC - James.
Thyroid cancer is usually treated surgically by removing the thyroid gland, followed by drinking radioactive iodine to kill any remaining cancer cells. Patients must then take synthetic thyroid hormone for life.
With all thyroid cells eliminated, the Tg level should be zero, and its presence later signals a possible return of the disease. (Sometimes, however, low levels of Tg can be present following treatment, and slowly decline over time.)
In the past, Tg testing required that patients stop taking their synthetic thyroid hormone several weeks before the test.
"That worked fairly well, except that some people became miserable after they stopped taking their synthetic thyroid hormone and became hypothyroid," Kloos says. "Some patients claimed that they'd rather die of their disease than go through that regularly."
Withdrawing from thyroid hormone can cause fatigue, weight gain, constipation, mental dullness, lethargy, depression and other symptoms.
Thyrogen, approved for use in 1998, allowed people to have a stimulated Tg test and continue taking the synthetic hormone.
The present study sought to help interpret the results of the Thyrogen-assisted Tg test. It involved 107 patients (88 women and 19 men; average age 36 years) treated for papillary, follicular or Hurthle cell thyroid cancer. Following surgery and radioactive iodine treatment, the patients were injected with Thyrogen and tested for Tg levels between January 1999 and March 2001.
The patients were divided into three groups based on their Tg reading. Group 1 patients had Tg levels below 0.5, group 2 had Tg levels of 0.6 to 2.0, and Group 3 had Tg levels greater than 2.0. (The numbers represent nanograms of Tg per milliliter of blood serum.)
After three to five years, the researchers found recurrent tumors in about 80 percent of the patients with Tg levels above 2.0, and in about 2 percent of those with Tg levels below 0.5.
An estimated 25,690 new cases of thyroid cancer are expected in 2005, with 19,190 of those expected to occur in women; 1,490 people are expected to die of the disease. In addition, about 330,000 living Americans have been treated for thyroid cancer, about 20 percent of whom are likely to have a recurrence.
Ernest L. Mazzaferri, OSU emeritus professor and chairman of medicine, was a co-author of the study.
Ohio State University
The test measures a protein known as thyroglobulin (Tg), which is made by thyroid-cancer cells. The measurement is taken after a person is injected with a relatively new drug known as thyrotropin alfa, or Thyrogen. The drug allows Tg testing without the sometimes debilitating side effects of hypothyroidism that otherwise accompany the test when stimulation testing is done.
"We were surprised to find that even with relatively low thyroglobulin levels, and even when there is no sign of a tumor, about 80 percent of patients had a recurrence of their cancer within three to five years," says first author Richard T. Kloos, associate professor of internal medicine and of radiology.
"This indicates that we are detecting these tumors very early, and that time and diligence may be needed to find them."
The study also found that even when Tg levels are very low or undetectable, about 2 to 5 percent of patients still have a recurrence after three to five years.
"Currently, some thyroid-cancer treatment guidelines say that these patients may never need further testing, but our data contradict that," says Kloos, co-director of the Thyroid Cancer Unit at the OSU CCC - James.
Thyroid cancer is usually treated surgically by removing the thyroid gland, followed by drinking radioactive iodine to kill any remaining cancer cells. Patients must then take synthetic thyroid hormone for life.
With all thyroid cells eliminated, the Tg level should be zero, and its presence later signals a possible return of the disease. (Sometimes, however, low levels of Tg can be present following treatment, and slowly decline over time.)
In the past, Tg testing required that patients stop taking their synthetic thyroid hormone several weeks before the test.
"That worked fairly well, except that some people became miserable after they stopped taking their synthetic thyroid hormone and became hypothyroid," Kloos says. "Some patients claimed that they'd rather die of their disease than go through that regularly."
Withdrawing from thyroid hormone can cause fatigue, weight gain, constipation, mental dullness, lethargy, depression and other symptoms.
Thyrogen, approved for use in 1998, allowed people to have a stimulated Tg test and continue taking the synthetic hormone.
The present study sought to help interpret the results of the Thyrogen-assisted Tg test. It involved 107 patients (88 women and 19 men; average age 36 years) treated for papillary, follicular or Hurthle cell thyroid cancer. Following surgery and radioactive iodine treatment, the patients were injected with Thyrogen and tested for Tg levels between January 1999 and March 2001.
The patients were divided into three groups based on their Tg reading. Group 1 patients had Tg levels below 0.5, group 2 had Tg levels of 0.6 to 2.0, and Group 3 had Tg levels greater than 2.0. (The numbers represent nanograms of Tg per milliliter of blood serum.)
After three to five years, the researchers found recurrent tumors in about 80 percent of the patients with Tg levels above 2.0, and in about 2 percent of those with Tg levels below 0.5.
An estimated 25,690 new cases of thyroid cancer are expected in 2005, with 19,190 of those expected to occur in women; 1,490 people are expected to die of the disease. In addition, about 330,000 living Americans have been treated for thyroid cancer, about 20 percent of whom are likely to have a recurrence.
Ernest L. Mazzaferri, OSU emeritus professor and chairman of medicine, was a co-author of the study.
Ohio State University
Thyroid Cancer News and Current Thyroid Cancer Events RSSResearchers discover atomic bomb effect results in adult-onset thyroid cancer
Radiation from the atomic bomb blasts in Hiroshima and Nagasaki, Japan, in 1945, likely rearranged chromosomes in some survivors who later developed papillary thyroid cancer as adults, according to Japanese researchers.
Scans spot hidden tumors in rare cancer syndrome
Researchers at Dana-Farber Cancer Institute report that full-body PET/CT scanning detected unsuspected, treatable tumors in 3 of 15 patients with Li-Fraumeni syndrome (LFS), a rare genetic cancer syndrome for which no screening tests have been recommended.
Mailman School PH study finds increase in thyroid diseases risk from exposure at Chernobyl
Persons exposed to radioactive fallout from the Chernobyl accident as children and adolescents have an increased risk of follicular adenoma or benign tumor of the thyroid gland, according to researchers at Columbia University Mailman School of Public Health.
Scientists solve structure of gene regulator that plays key role in cancer
Scientists at The Wistar Institute have collaborated on a major advance in understanding a gene regulator that contributes to some of the deadliest cancers in humans. The culmination of 10 years' work, their research paves the way for the development of new cancer therapies.
Presence of gene mutation helps guide thyroid cancer treatment
A specific gene mutation may be useful in predicting the level of aggression of thyroid cancer and help guide treatment options and follow-up care, according to new study findings.
Role of Thyroid Hormones in Slumber Under Investigation at Rutgers-Camden
While the thyroid has long been linked to metabolism, cutting-edge research underway at Rutgers University-Camden is investigating the possibility that thyroid hormones have an important role in sleep regulation.
Ethanol injection helps manage bone metastasis in thyroid cancer patients
Percutaneous ethanol injection (PEI)-an injection of ethanol (alcohol) through the skin directly into a bone tumor to kill cancer cells-may be a valuable ancillary treatment for thyroid cancer patients whose cancer has spread to the bone. Japanese researchers announced these findings during the 54th Annual Meeting of SNM, the world's largest society for molecular imaging and nuclear medicine.
Hepatitis C increases risk of non-Hodgkin lymphoma
Hepatitis C infection is associated with an increased risk of non-Hodgkin lymphoma (malignancy involving lymphatic tissue) of 20 percent to 30 percent, and a three-fold increase in the risk of another type of lymphoma, according to a study in the May 9 issue of JAMA.
Lung cancer rates higher among female nonsmokers than previously
Not all lung cancer is due to a lifetime of smoking cigarettes. Sometimes the diagnosis is a mystery, and the stigma surrounding the disease makes it hard for patients to talk about.
Thyroid cancer discovery points to new treatments, prevention
The actions of a mutated protein in cells linked to thyroid cancer have been uncovered by researchers at Queen's University.
More Thyroid Cancer News Articles
 | Breast Cancer and Iodine : How to Prevent and How to Survive Breast Cancer by Dr. David Derry M.D., Ph.D. This book is about cause, prevention and treatment of breast cancer. Breast cancer has two phases. The first one, from abnormal cells up to carcinoma in situ reverses with iodine. The second phase, invasion, is controlled by connective tissue thyroid... |
 | Thyroid Cancer: A Guide for Patients This book is a valuable and extensive source of information about thyroid cancer and is specifically written for the patient with thyroid cancer. However, family and friends of patients who have thyroid cancer will also find this book useful. The book discusses a wide spectrum of aspects about thyroid nodules and cancer. It is discusses the basics of the thyroid gland, the evaluation of... |
 | The Thyroid Cancer Book by M. Sara Rosenthal, Ph.D. Now in its second edition, the only consumer book on thyroid cancer in plain language, also contains a Low Iodine Cookbook. Recommended by Johns Hopkins Thyroid Tumor Center, The Thyroid Foundation of America, The American Foundation for Thyroid Patients, The Thyroid Foundation of Canada, CancerHelpUK, and thyroid cancer patients from both Thyca and... |
 | Thyroid Cancer by Alan Elias M.D. Thyroid cancer is a relatively uncommon cancer although its incidence is increasing particularly among women. Because of the slow pace of spread of differentiated thyroid cancers a one-size fits all approach to the management of patients with this cancer is to be avoided. In this brief outline of the various types of thyroid cancer and their treatment the author has attempted to provide the... |
 | The Purple Butterfly: Diary of a thyroid cancer patient by Susan Hibberd 'The Purple Butterfly' cameos a year in the life of a thyroid cancer patient. Restrained and sparsely written, it gives the reader a deep insight into the mind of someone who is balancing on the edge of hysteria, yet still feels an obligation to `put on a brave face'. A 'must-read' for anyone supporting a friend or relative through a serious illness - this book tells you what he or she never... |
 | Quick FACTS Thyroid Cancer (Quickfacts) by American Cancer Society What people need to know-right from the start-about their Thyroid cancer More than 1.3 million Americans will be diagnosed with various forms of cancer this year. They, their families, and their caregivers will all be seeking information about their specific cancer type. This guide from the experts at the American Cancer Society gives them what they need to know, right from the... |
 | Thyroid Cancer in Clinical Practice by I. Ross McDougall The book covers all aspects of thyroid cancer, including nodules, pathology, thyroid and whole-body scans, ultrasounds, and other nuclear medicine and radiological studies, as well as follow-up testing and prognosis. It tackles the treatment of differentiated thyroid cancer (the commonest variety) and all aspects of the management including surgery, the role and logistics of radioactive iodine... |
 | Package - The Thyroid Cancer Book and The Low Iodine Diet Cookbook by M. Sara Rosenthal, Norene Gilletz Get both books at a one low... |
 | The Genetics of Complex Thyroid Diseases The autoimmune thyroid diseases and familial thyroid cancers are the current target of molecular thyroid genetics. Unlike the situation in monogenic thyroid diseases, for which the molecular genetics has largely been clarified over the past 20 years, a methodological approach to these more complex forms of thyroid disease has not yet been well established. The determination of susceptibility... |
 | Practical Management of Thyroid Cancer: A Multidisciplinary Approach Written by a multidisciplinary team of experts involved in the development of standards and guidelines for its management in the USA, UK, Europe and Asia, the book contains succinct and knowledgeable summaries of the management of thyroid cancer. Every chapter describes a different aspect of care, and provides clear and detailed information about caring for patients with this group of tumors. ... |
| © 2008 BrightSurf.com |